#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Protein
2-1	16-23	Protein	substance	new	coref	4-2

#Text=N-glycosylation is a critical post-translational modification , in which an oligosaccharide moiety is transferred from the glycosyl carrier dolichol-phosphate ( Dol-P ) and covalently attaches to a polypeptide chain via an asparagine residue .
3-1	24-39	N-glycosylation	abstract	new	coref	3-3[4_0]
3-2	40-42	is	_	_	_	_
3-3	43-44	a	abstract[4]	giv[4]	coref	5-3[20_4]
3-4	45-53	critical	abstract[4]	giv[4]	_	_
3-5	54-72	post-translational	abstract[4]	giv[4]	_	_
3-6	73-85	modification	abstract[4]	giv[4]	_	_
3-7	86-87	,	_	_	_	_
3-8	88-90	in	_	_	_	_
3-9	91-96	which	_	_	_	_
3-10	97-99	an	substance[6]	new[6]	_	_
3-11	100-115	oligosaccharide	abstract|substance[6]	new|new[6]	coref	4-5[17_0]
3-12	116-122	moiety	substance[6]	new[6]	_	_
3-13	123-125	is	_	_	_	_
3-14	126-137	transferred	_	_	_	_
3-15	138-142	from	_	_	_	_
3-16	143-146	the	person[9]	new[9]	_	_
3-17	147-155	glycosyl	abstract|person[9]	new|new[9]	_	_
3-18	156-163	carrier	organization|person[9]	new|new[9]	_	_
3-19	164-182	dolichol-phosphate	person[9]	new[9]	_	_
3-20	183-184	(	_	_	_	_
3-21	185-190	Dol-P	object	new	coref	8-21
3-22	191-192	)	_	_	_	_
3-23	193-196	and	_	_	_	_
3-24	197-207	covalently	_	_	_	_
3-25	208-216	attaches	_	_	_	_
3-26	217-219	to	_	_	_	_
3-27	220-221	a	abstract[12]	new[12]	coref	9-5[0_12]
3-28	222-233	polypeptide	place|abstract[12]	new|new[12]	_	_
3-29	234-239	chain	abstract[12]	new[12]	_	_
3-30	240-243	via	abstract[12]	new[12]	_	_
3-31	244-246	an	abstract[12]|object[14]	new[12]|new[14]	_	_
3-32	247-257	asparagine	abstract[12]|substance|object[14]	new[12]|new|new[14]	_	_
3-33	258-265	residue	abstract[12]|object[14]	new[12]|new[14]	_	_
3-34	266-267	.	_	_	_	_

#Text=Following protein conjugation , the oligosaccharide is further modified , increasing the functional and structural diversity of the proteome .
4-1	268-277	Following	_	_	_	_
4-2	278-285	protein	substance|abstract[16]	giv|new[16]	coref	5-9
4-3	286-297	conjugation	abstract[16]	new[16]	_	_
4-4	298-299	,	_	_	_	_
4-5	300-303	the	abstract[17]	giv[17]	_	_
4-6	304-319	oligosaccharide	abstract[17]	giv[17]	_	_
4-7	320-322	is	_	_	_	_
4-8	323-330	further	_	_	_	_
4-9	331-339	modified	_	_	_	_
4-10	340-341	,	_	_	_	_
4-11	342-352	increasing	_	_	_	_
4-12	353-356	the	abstract[18]	new[18]	_	_
4-13	357-367	functional	abstract[18]	new[18]	_	_
4-14	368-371	and	abstract[18]	new[18]	_	_
4-15	372-382	structural	abstract[18]	new[18]	_	_
4-16	383-392	diversity	abstract[18]	new[18]	_	_
4-17	393-395	of	abstract[18]	new[18]	_	_
4-18	396-399	the	abstract[18]|object[19]	new[18]|new[19]	_	_
4-19	400-408	proteome	abstract[18]|object[19]	new[18]|new[19]	_	_
4-20	409-410	.	_	_	_	_

#Text=Indeed , this modification is crucial for proper protein folding , oligomerization , quality control , sorting , and transport .
5-1	411-417	Indeed	_	_	_	_
5-2	418-419	,	_	_	_	_
5-3	420-424	this	abstract[20]	giv[20]	_	_
5-4	425-437	modification	abstract[20]	giv[20]	_	_
5-5	438-440	is	_	_	_	_
5-6	441-448	crucial	_	_	_	_
5-7	449-452	for	_	_	_	_
5-8	453-459	proper	abstract[22]	new[22]	_	_
5-9	460-467	protein	substance|abstract[22]	giv|new[22]	coref	6-7
5-10	468-475	folding	abstract[22]	new[22]	_	_
5-11	476-477	,	_	_	_	_
5-12	478-493	oligomerization	place	new	_	_
5-13	494-495	,	_	_	_	_
5-14	496-503	quality	abstract[24]	new[24]	_	_
5-15	504-511	control	abstract[24]	new[24]	_	_
5-16	512-513	,	_	_	_	_
5-17	514-521	sorting	abstract	new	_	_
5-18	522-523	,	_	_	_	_
5-19	524-527	and	_	_	_	_
5-20	528-537	transport	abstract	new	_	_
5-21	538-539	.	_	_	_	_

#Text=Accordingly , even slight variations in protein glycosylation can markedly affect proteins structure and function and , thus , glycosylation disorders result in a wide range of clinical syndromes affecting practically every organ system .
6-1	540-551	Accordingly	_	_	_	_
6-2	552-553	,	_	_	_	_
6-3	554-558	even	abstract[27]	new[27]	_	_
6-4	559-565	slight	abstract[27]	new[27]	_	_
6-5	566-576	variations	abstract[27]	new[27]	_	_
6-6	577-579	in	abstract[27]	new[27]	_	_
6-7	580-587	protein	abstract[27]|substance|abstract[29]	new[27]|giv|new[29]	coref|coref	6-20[0_29]|13-10
6-8	588-601	glycosylation	abstract[27]|abstract[29]	new[27]|new[29]	_	_
6-9	602-605	can	_	_	_	_
6-10	606-614	markedly	_	_	_	_
6-11	615-621	affect	_	_	_	_
6-12	622-630	proteins	substance|abstract[31]|abstract[32]	new|new[31]|new[32]	coref|coref	21-3[123_31]|21-3[124_32]
6-13	631-640	structure	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-14	641-644	and	abstract[32]	new[32]	_	_
6-15	645-653	function	abstract[32]|abstract	new[32]|new	_	_
6-16	654-657	and	_	_	_	_
6-17	658-659	,	_	_	_	_
6-18	660-664	thus	_	_	_	_
6-19	665-666	,	_	_	_	_
6-20	667-680	glycosylation	abstract	giv	coref	13-10[75_0]
6-21	681-690	disorders	abstract	new	_	_
6-22	691-697	result	_	_	_	_
6-23	698-700	in	_	_	_	_
6-24	701-702	a	abstract[36]	new[36]	_	_
6-25	703-707	wide	abstract[36]	new[36]	_	_
6-26	708-713	range	abstract[36]	new[36]	_	_
6-27	714-716	of	abstract[36]	new[36]	_	_
6-28	717-725	clinical	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-29	726-735	syndromes	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-30	736-745	affecting	_	_	_	_
6-31	746-757	practically	_	_	_	_
6-32	758-763	every	abstract[39]	new[39]	_	_
6-33	764-769	organ	abstract|abstract[39]	new|new[39]	_	_
6-34	770-776	system	abstract[39]	new[39]	_	_
6-35	777-778	.	_	_	_	_

#Text=Dehydrodolichyl diphosphate synthase ( DHDDS ) together with Nogo-B receptor ( NgBR ) form the human cis -prenyltransferase complex .
7-1	779-794	Dehydrodolichyl	abstract[41]	new[41]	coref	15-23[96_41]
7-2	795-806	diphosphate	person|abstract[41]	new|new[41]	coref	9-8[57_0]
7-3	807-815	synthase	abstract[41]	new[41]	_	_
7-4	816-817	(	_	_	_	_
7-5	818-823	DHDDS	place	new	coref	12-8
7-6	824-825	)	_	_	_	_
7-7	826-834	together	substance[44]	new[44]	_	_
7-8	835-839	with	substance[44]	new[44]	_	_
7-9	840-846	Nogo-B	abstract|substance[44]	new|new[44]	_	_
7-10	847-855	receptor	substance[44]	new[44]	_	_
7-11	856-857	(	_	_	_	_
7-12	858-862	NgBR	abstract	new	coref	12-18
7-13	863-864	)	_	_	_	_
7-14	865-869	form	event	new	coref|none	8-4[47_0]|7-14[0_47]
7-15	870-873	the	_	_	_	_
7-16	874-879	human	_	_	_	_
7-17	880-883	cis	_	_	_	_
7-18	884-902	-prenyltransferase	_	_	_	_
7-19	903-910	complex	_	_	_	_
7-20	911-912	.	_	_	_	_

#Text=This complex catalyzes the formation of dehydrodolichyl diphosphate ( DHDD ) , a long-chain polyprenyl serving as a precursor for Dol-P .
8-1	913-917	This	object[46]	new[46]	_	_
8-2	918-925	complex	object[46]	new[46]	_	_
8-3	926-935	catalyzes	_	_	_	_
8-4	936-939	the	event[47]	new[47]	_	_
8-5	940-949	formation	event[47]	new[47]	_	_
8-6	950-952	of	event[47]	new[47]	_	_
8-7	953-968	dehydrodolichyl	event[47]|abstract|abstract[49]	new[47]|new|new[49]	_	_
8-8	969-980	diphosphate	event[47]|abstract[49]	new[47]|new[49]	_	_
8-9	981-982	(	_	_	_	_
8-10	983-987	DHDD	place	new	coref	9-1
8-11	988-989	)	_	_	_	_
8-12	990-991	,	_	_	_	_
8-13	992-993	a	substance[51]	new[51]	_	_
8-14	994-1004	long-chain	substance[51]	new[51]	_	_
8-15	1005-1015	polyprenyl	substance[51]	new[51]	_	_
8-16	1016-1023	serving	_	_	_	_
8-17	1024-1026	as	_	_	_	_
8-18	1027-1028	a	_	_	_	_
8-19	1029-1038	precursor	_	_	_	_
8-20	1039-1042	for	_	_	_	_
8-21	1043-1048	Dol-P	substance	giv	_	_
8-22	1049-1050	.	_	_	_	_

#Text=DHDD is synthesized by chain elongation of farnesyl diphosphate ( FPP ) via multiple condensations with isopentenyl diphosphate ( IPP ) (
9-1	1051-1055	DHDD	abstract	giv	_	_
9-2	1056-1058	is	_	_	_	_
9-3	1059-1070	synthesized	_	_	_	_
9-4	1071-1073	by	_	_	_	_
9-5	1074-1079	chain	abstract|abstract[55]	giv|new[55]	_	_
9-6	1080-1090	elongation	abstract[55]	new[55]	_	_
9-7	1091-1093	of	abstract[55]	new[55]	_	_
9-8	1094-1102	farnesyl	abstract[55]|abstract|person[57]	new[55]|new|giv[57]	coref	9-17[61_57]
9-9	1103-1114	diphosphate	abstract[55]|person[57]	new[55]|giv[57]	_	_
9-10	1115-1116	(	_	_	_	_
9-11	1117-1120	FPP	substance	new	_	_
9-12	1121-1122	)	_	_	_	_
9-13	1123-1126	via	_	_	_	_
9-14	1127-1135	multiple	substance[59]	new[59]	_	_
9-15	1136-1149	condensations	substance[59]	new[59]	_	_
9-16	1150-1154	with	substance[59]	new[59]	_	_
9-17	1155-1166	isopentenyl	substance[59]|abstract|person[61]	new[59]|new|giv[61]	_	_
9-18	1167-1178	diphosphate	substance[59]|person[61]	new[59]|giv[61]	_	_
9-19	1179-1180	(	_	_	_	_
9-20	1181-1184	IPP	abstract	new	_	_
9-21	1185-1186	)	_	_	_	_
9-22	1187-1188	(	_	_	_	_

#Text=Figure 1
10-1	1189-1195	Figure	object[63]	new[63]	coref	19-1[120_63]
10-2	1196-1197	1	object[63]	new[63]	_	_

#Text=A ) .
11-1	1198-1199	A	_	_	_	_
11-2	1200-1201	)	_	_	_	_
11-3	1202-1203	.	_	_	_	_

#Text=Importantly , while previous studies revealed that DHDDS is required and sufficient for this catalytic activity , NgBR induces an increase in the expression and activity of the complex but exhibits no catalytic activity .
12-1	1204-1215	Importantly	_	_	_	_
12-2	1216-1217	,	_	_	_	_
12-3	1218-1223	while	_	_	_	_
12-4	1224-1232	previous	abstract[64]	new[64]	_	_
12-5	1233-1240	studies	abstract[64]	new[64]	_	_
12-6	1241-1249	revealed	_	_	_	_
12-7	1250-1254	that	_	_	_	_
12-8	1255-1260	DHDDS	place	giv	coref	13-8[73_0]
12-9	1261-1263	is	_	_	_	_
12-10	1264-1272	required	_	_	_	_
12-11	1273-1276	and	_	_	_	_
12-12	1277-1287	sufficient	_	_	_	_
12-13	1288-1291	for	_	_	_	_
12-14	1292-1296	this	abstract[66]	new[66]	coref	12-26[70_66]
12-15	1297-1306	catalytic	abstract[66]	new[66]	_	_
12-16	1307-1315	activity	abstract[66]	new[66]	_	_
12-17	1316-1317	,	_	_	_	_
12-18	1318-1322	NgBR	substance	giv	_	_
12-19	1323-1330	induces	_	_	_	_
12-20	1331-1333	an	event[68]	new[68]	_	_
12-21	1334-1342	increase	event[68]	new[68]	_	_
12-22	1343-1345	in	event[68]	new[68]	_	_
12-23	1346-1349	the	event[68]|abstract[69]	new[68]|new[69]	_	_
12-24	1350-1360	expression	event[68]|abstract[69]	new[68]|new[69]	_	_
12-25	1361-1364	and	event[68]	new[68]	_	_
12-26	1365-1373	activity	event[68]|abstract[70]	new[68]|giv[70]	coref	12-32[71_70]
12-27	1374-1376	of	event[68]|abstract[70]	new[68]|giv[70]	_	_
12-28	1377-1380	the	event[68]|abstract[70]	new[68]|giv[70]	_	_
12-29	1381-1388	complex	event[68]|abstract[70]	new[68]|giv[70]	_	_
12-30	1389-1392	but	_	_	_	_
12-31	1393-1401	exhibits	_	_	_	_
12-32	1402-1404	no	abstract[71]	giv[71]	_	_
12-33	1405-1414	catalytic	abstract[71]	giv[71]	_	_
12-34	1415-1423	activity	abstract[71]	giv[71]	_	_
12-35	1424-1425	.	_	_	_	_

#Text=In line with the important role of DHDDS in protein glycosylation , mutations in DHDDS were recently shown to cause autosomal recessive retinitis pigmentosa , a fatal glycosylation disorder , and developmental epileptic encephalopathies .
13-1	1426-1428	In	_	_	_	_
13-2	1429-1433	line	_	_	_	_
13-3	1434-1438	with	_	_	_	_
13-4	1439-1442	the	abstract[72]	new[72]	coref	21-6[125_72]
13-5	1443-1452	important	abstract[72]	new[72]	_	_
13-6	1453-1457	role	abstract[72]	new[72]	_	_
13-7	1458-1460	of	abstract[72]	new[72]	_	_
13-8	1461-1466	DHDDS	abstract[72]|place[73]	new[72]|giv[73]	coref	13-15[0_73]
13-9	1467-1469	in	abstract[72]|place[73]	new[72]|giv[73]	_	_
13-10	1470-1477	protein	abstract[72]|place[73]|substance|abstract[75]	new[72]|giv[73]|giv|giv[75]	coref	13-28[0_75]
13-11	1478-1491	glycosylation	abstract[72]|place[73]|abstract[75]	new[72]|giv[73]|giv[75]	_	_
13-12	1492-1493	,	_	_	_	_
13-13	1494-1503	mutations	abstract[76]	new[76]	_	_
13-14	1504-1506	in	abstract[76]	new[76]	_	_
13-15	1507-1512	DHDDS	abstract[76]|abstract	new[76]|giv	coref	14-6
13-16	1513-1517	were	_	_	_	_
13-17	1518-1526	recently	_	_	_	_
13-18	1527-1532	shown	_	_	_	_
13-19	1533-1535	to	_	_	_	_
13-20	1536-1541	cause	_	_	_	_
13-21	1542-1551	autosomal	animal	new	_	_
13-22	1552-1561	recessive	object[80]	new[80]	_	_
13-23	1562-1571	retinitis	abstract|object[80]	new|new[80]	_	_
13-24	1572-1582	pigmentosa	object[80]	new[80]	_	_
13-25	1583-1584	,	_	_	_	_
13-26	1585-1586	a	abstract[82]	new[82]	_	_
13-27	1587-1592	fatal	abstract[82]	new[82]	_	_
13-28	1593-1606	glycosylation	abstract|abstract[82]	giv|new[82]	_	_
13-29	1607-1615	disorder	abstract[82]	new[82]	_	_
13-30	1616-1617	,	_	_	_	_
13-31	1618-1621	and	_	_	_	_
13-32	1622-1635	developmental	abstract[83]	new[83]	_	_
13-33	1636-1645	epileptic	abstract[83]	new[83]	_	_
13-34	1646-1662	encephalopathies	abstract[83]	new[83]	_	_
13-35	1663-1664	.	_	_	_	_

#Text=Despite the clinical importance of DHDDS , it was not structurally and functionally characterized to date .
14-1	1665-1672	Despite	_	_	_	_
14-2	1673-1676	the	abstract[84]	new[84]	_	_
14-3	1677-1685	clinical	abstract[84]	new[84]	_	_
14-4	1686-1696	importance	abstract[84]	new[84]	_	_
14-5	1697-1699	of	abstract[84]	new[84]	_	_
14-6	1700-1705	DHDDS	abstract[84]|abstract	new[84]|giv	ana	14-8
14-7	1706-1707	,	_	_	_	_
14-8	1708-1710	it	abstract	giv	coref	15-13
14-9	1711-1714	was	_	_	_	_
14-10	1715-1718	not	_	_	_	_
14-11	1719-1731	structurally	_	_	_	_
14-12	1732-1735	and	_	_	_	_
14-13	1736-1748	functionally	_	_	_	_
14-14	1749-1762	characterized	_	_	_	_
14-15	1763-1765	to	_	_	_	_
14-16	1766-1770	date	time	new	_	_
14-17	1771-1772	.	_	_	_	_

#Text=Conserved domains search analysis reveals that the cis -prenyltransferase catalytic domain of DHDDS ( residues 24 – 248 ) is homologous to undecaprenyl pyrophosphate synthase ( UPPS ) , a well characterized bacterial cis -prenyltransferase .
15-1	1773-1782	Conserved	abstract[88]	new[88]	coref	17-20[114_88]
15-2	1783-1790	domains	abstract[88]	new[88]	_	_
15-3	1791-1797	search	_	_	_	_
15-4	1798-1806	analysis	abstract	new	_	_
15-5	1807-1814	reveals	_	_	_	_
15-6	1815-1819	that	_	_	_	_
15-7	1820-1823	the	abstract[90]	new[90]	appos	15-15[92_90]
15-8	1824-1827	cis	abstract[90]	new[90]	_	_
15-9	1828-1846	-prenyltransferase	abstract[90]	new[90]	_	_
15-10	1847-1856	catalytic	abstract[90]	new[90]	_	_
15-11	1857-1863	domain	abstract[90]	new[90]	_	_
15-12	1864-1866	of	abstract[90]	new[90]	_	_
15-13	1867-1872	DHDDS	abstract[90]|place	new[90]|giv	coref	17-14[113_0]
15-14	1873-1874	(	_	_	_	_
15-15	1875-1883	residues	abstract[92]	giv[92]	coref	16-9[102_92]
15-16	1884-1886	24	abstract[92]	giv[92]	_	_
15-17	1887-1888	–	abstract[92]	giv[92]	_	_
15-18	1889-1892	248	abstract[92]|quantity	giv[92]|new	_	_
15-19	1893-1894	)	_	_	_	_
15-20	1895-1897	is	_	_	_	_
15-21	1898-1908	homologous	_	_	_	_
15-22	1909-1911	to	_	_	_	_
15-23	1912-1924	undecaprenyl	abstract|abstract[96]	new|giv[96]	appos	15-27[0_96]
15-24	1925-1938	pyrophosphate	person|abstract[96]	new|giv[96]	_	_
15-25	1939-1947	synthase	abstract[96]	giv[96]	_	_
15-26	1948-1949	(	_	_	_	_
15-27	1950-1954	UPPS	abstract	giv	coref	23-5[132_0]
15-28	1955-1956	)	_	_	_	_
15-29	1957-1958	,	_	_	_	_
15-30	1959-1960	a	object[99]	new[99]	_	_
15-31	1961-1965	well	object[99]	new[99]	_	_
15-32	1966-1979	characterized	object[99]	new[99]	_	_
15-33	1980-1989	bacterial	substance|object[99]	new|new[99]	coref	23-3[131_0]
15-34	1990-1993	cis	object[99]	new[99]	_	_
15-35	1994-2012	-prenyltransferase	object[99]	new[99]	_	_
15-36	2013-2014	.	_	_	_	_

#Text=Consisting of seven α-helices and six β-strands , this domain forms dimers , with a hydrophobic catalytic tunnel surrounded by two α-helices and four β−strands within each monomer .
16-1	2015-2025	Consisting	_	_	_	_
16-2	2026-2028	of	_	_	_	_
16-3	2029-2034	seven	quantity[100]	new[100]	_	_
16-4	2035-2044	α-helices	quantity[100]	new[100]	_	_
16-5	2045-2048	and	_	_	_	_
16-6	2049-2052	six	place[101]	new[101]	_	_
16-7	2053-2062	β-strands	place[101]	new[101]	_	_
16-8	2063-2064	,	_	_	_	_
16-9	2065-2069	this	abstract[102]	giv[102]	coref	17-4[111_102]
16-10	2070-2076	domain	abstract[102]	giv[102]	_	_
16-11	2077-2082	forms	_	_	_	_
16-12	2083-2089	dimers	object	new	_	_
16-13	2090-2091	,	_	_	_	_
16-14	2092-2096	with	_	_	_	_
16-15	2097-2098	a	object[104]	new[104]	_	_
16-16	2099-2110	hydrophobic	object[104]	new[104]	_	_
16-17	2111-2120	catalytic	object[104]	new[104]	_	_
16-18	2121-2127	tunnel	object[104]	new[104]	_	_
16-19	2128-2138	surrounded	_	_	_	_
16-20	2139-2141	by	_	_	_	_
16-21	2142-2145	two	substance[105]	new[105]	_	_
16-22	2146-2155	α-helices	substance[105]	new[105]	_	_
16-23	2156-2159	and	_	_	_	_
16-24	2160-2164	four	substance[106]	new[106]	_	_
16-25	2165-2174	β−strands	substance[106]	new[106]	_	_
16-26	2175-2181	within	substance[106]	new[106]	_	_
16-27	2182-2186	each	substance[106]|object[107]	new[106]|new[107]	_	_
16-28	2187-2194	monomer	substance[106]|object[107]	new[106]|new[107]	_	_
16-29	2195-2196	.	_	_	_	_

#Text=In contrast with the N-terminal cis -prenyltransferase homology domain , the C-terminus of human DHDDS does not converge with any known conserved domains .
17-1	2197-2199	In	_	_	_	_
17-2	2200-2208	contrast	abstract[108]	new[108]	_	_
17-3	2209-2213	with	abstract[108]	new[108]	_	_
17-4	2214-2217	the	abstract[108]|abstract[111]	new[108]|giv[111]	coref	18-10[117_111]
17-5	2218-2228	N-terminal	abstract[108]|place|abstract[111]	new[108]|new|giv[111]	_	_
17-6	2229-2232	cis	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
17-7	2233-2251	-prenyltransferase	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
17-8	2252-2260	homology	abstract[108]|abstract|abstract[111]	new[108]|new|giv[111]	_	_
17-9	2261-2267	domain	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
17-10	2268-2269	,	_	_	_	_
17-11	2270-2273	the	abstract[112]	new[112]	_	_
17-12	2274-2284	C-terminus	abstract[112]	new[112]	_	_
17-13	2285-2287	of	abstract[112]	new[112]	_	_
17-14	2288-2293	human	abstract[112]|place[113]	new[112]|giv[113]	coref	22-14[130_113]
17-15	2294-2299	DHDDS	abstract[112]|place[113]	new[112]|giv[113]	_	_
17-16	2300-2304	does	_	_	_	_
17-17	2305-2308	not	_	_	_	_
17-18	2309-2317	converge	_	_	_	_
17-19	2318-2322	with	_	_	_	_
17-20	2323-2326	any	abstract[114]	giv[114]	_	_
17-21	2327-2332	known	abstract[114]	giv[114]	_	_
17-22	2333-2342	conserved	abstract[114]	giv[114]	_	_
17-23	2343-2350	domains	abstract[114]	giv[114]	_	_
17-24	2351-2352	.	_	_	_	_

#Text=Intriguingly , despite the low level of conservation , a C-terminal domain is common to long-chain cis -prenyltransferases and is absent in short- and medium-chain cis -prenyltransferases (
18-1	2353-2365	Intriguingly	_	_	_	_
18-2	2366-2367	,	_	_	_	_
18-3	2368-2375	despite	_	_	_	_
18-4	2376-2379	the	abstract[115]	new[115]	_	_
18-5	2380-2383	low	abstract[115]	new[115]	_	_
18-6	2384-2389	level	abstract[115]	new[115]	_	_
18-7	2390-2392	of	abstract[115]	new[115]	_	_
18-8	2393-2405	conservation	abstract[115]|abstract	new[115]|new	_	_
18-9	2406-2407	,	_	_	_	_
18-10	2408-2409	a	abstract[117]	giv[117]	_	_
18-11	2410-2420	C-terminal	abstract[117]	giv[117]	_	_
18-12	2421-2427	domain	abstract[117]	giv[117]	_	_
18-13	2428-2430	is	_	_	_	_
18-14	2431-2437	common	_	_	_	_
18-15	2438-2440	to	_	_	_	_
18-16	2441-2451	long-chain	object[118]	new[118]	coref	18-23[119_118]
18-17	2452-2455	cis	object[118]	new[118]	_	_
18-18	2456-2475	-prenyltransferases	object[118]	new[118]	_	_
18-19	2476-2479	and	_	_	_	_
18-20	2480-2482	is	_	_	_	_
18-21	2483-2489	absent	_	_	_	_
18-22	2490-2492	in	_	_	_	_
18-23	2493-2499	short-	object[119]	giv[119]	_	_
18-24	2500-2503	and	object[119]	giv[119]	_	_
18-25	2504-2516	medium-chain	object[119]	giv[119]	_	_
18-26	2517-2520	cis	object[119]	giv[119]	_	_
18-27	2521-2540	-prenyltransferases	object[119]	giv[119]	_	_
18-28	2541-2542	(	_	_	_	_

#Text=Figure 1
19-1	2543-2549	Figure	object[120]	giv[120]	ana	21-3[0_120]
19-2	2550-2551	1	object[120]	giv[120]	_	_

#Text=B ) .
20-1	2552-2553	B	person	new	_	_
20-2	2554-2555	)	_	_	_	_
20-3	2556-2557	.	_	_	_	_

#Text=Nevertheless , its structure and functional role remains elusive .
21-1	2558-2570	Nevertheless	_	_	_	_
21-2	2571-2572	,	_	_	_	_
21-3	2573-2576	its	object|abstract[123]|abstract[124]	giv|giv[123]|giv[124]	_	_
21-4	2577-2586	structure	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
21-5	2587-2590	and	abstract[124]	giv[124]	_	_
21-6	2591-2601	functional	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
21-7	2602-2606	role	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
21-8	2607-2614	remains	_	_	_	_
21-9	2615-2622	elusive	_	_	_	_
21-10	2623-2624	.	_	_	_	_

#Text=Recently , we have devised an efficient procedure for overexpression and purification of human DHDDS in Escherichia coli .
22-1	2625-2633	Recently	_	_	_	_
22-2	2634-2635	,	_	_	_	_
22-3	2636-2638	we	person	acc	ana	23-8
22-4	2639-2643	have	_	_	_	_
22-5	2644-2651	devised	_	_	_	_
22-6	2652-2654	an	abstract[127]	new[127]	_	_
22-7	2655-2664	efficient	abstract[127]	new[127]	_	_
22-8	2665-2674	procedure	abstract[127]	new[127]	_	_
22-9	2675-2678	for	abstract[127]	new[127]	_	_
22-10	2679-2693	overexpression	abstract[127]|abstract	new[127]|new	_	_
22-11	2694-2697	and	abstract[127]	new[127]	_	_
22-12	2698-2710	purification	abstract[127]|event[129]	new[127]|new[129]	_	_
22-13	2711-2713	of	abstract[127]|event[129]	new[127]|new[129]	_	_
22-14	2714-2719	human	abstract[127]|event[129]|place[130]	new[127]|new[129]|giv[130]	coref	23-11[134_130]
22-15	2720-2725	DHDDS	abstract[127]|event[129]|place[130]	new[127]|new[129]|giv[130]	_	_
22-16	2726-2728	in	abstract[127]|event[129]|place[130]	new[127]|new[129]|giv[130]	_	_
22-17	2729-2740	Escherichia	abstract[127]|event[129]|place[130]	new[127]|new[129]|giv[130]	_	_
22-18	2741-2745	coli	abstract[127]|event[129]|place[130]	new[127]|new[129]|giv[130]	_	_
22-19	2746-2747	.	_	_	_	_

#Text=Similar to the bacterial homolog UPPS , we showed that human DHDDS forms active homodimers .
23-1	2748-2755	Similar	_	_	_	_
23-2	2756-2758	to	_	_	_	_
23-3	2759-2762	the	substance[131]	giv[131]	_	_
23-4	2763-2772	bacterial	substance[131]	giv[131]	_	_
23-5	2773-2780	homolog	abstract[132]	giv[132]	_	_
23-6	2781-2785	UPPS	abstract[132]	giv[132]	_	_
23-7	2786-2787	,	_	_	_	_
23-8	2788-2790	we	person	giv	ana	25-3
23-9	2791-2797	showed	_	_	_	_
23-10	2798-2802	that	_	_	_	_
23-11	2803-2808	human	abstract[134]	giv[134]	coref	25-12[0_134]
23-12	2809-2814	DHDDS	abstract[134]	giv[134]	_	_
23-13	2815-2820	forms	_	_	_	_
23-14	2821-2827	active	object[135]	new[135]	_	_
23-15	2828-2838	homodimers	object[135]	new[135]	_	_
23-16	2839-2840	.	_	_	_	_

#Text=However , the molecular details of the interaction interface and the overall architecture of the enzyme remained obscure .
24-1	2841-2848	However	_	_	_	_
24-2	2849-2850	,	_	_	_	_
24-3	2851-2854	the	abstract[136]	new[136]	_	_
24-4	2855-2864	molecular	abstract[136]	new[136]	_	_
24-5	2865-2872	details	abstract[136]	new[136]	_	_
24-6	2873-2875	of	abstract[136]	new[136]	_	_
24-7	2876-2879	the	abstract[136]|abstract[138]	new[136]|new[138]	_	_
24-8	2880-2891	interaction	abstract[136]|abstract|abstract[138]	new[136]|new|new[138]	_	_
24-9	2892-2901	interface	abstract[136]|abstract[138]	new[136]|new[138]	_	_
24-10	2902-2905	and	abstract[136]	new[136]	_	_
24-11	2906-2909	the	abstract[136]|abstract[139]	new[136]|new[139]	_	_
24-12	2910-2917	overall	abstract[136]|abstract[139]	new[136]|new[139]	_	_
24-13	2918-2930	architecture	abstract[136]|abstract[139]	new[136]|new[139]	_	_
24-14	2931-2933	of	abstract[136]|abstract[139]	new[136]|new[139]	_	_
24-15	2934-2937	the	abstract[136]|abstract[139]|object[140]	new[136]|new[139]|new[140]	coref	25-28[0_140]
24-16	2938-2944	enzyme	abstract[136]|abstract[139]|object[140]	new[136]|new[139]|new[140]	_	_
24-17	2945-2953	remained	_	_	_	_
24-18	2954-2961	obscure	_	_	_	_
24-19	2962-2963	.	_	_	_	_

#Text=Here , we determine a structural model for the full-length human DHDDS homodimer using an integrative approach that combines multiple sources of information , including a radioligand-based enzyme kinetics assay , size-exclusion chromatography multi-angle light scattering ( SEC-MALS ) , small-angle X-ray scattering ( SAXS ) , and hydrogen – deuterium exchange mass-spectrometry ( HDX-MS ) .
25-1	2964-2968	Here	_	_	_	_
25-2	2969-2970	,	_	_	_	_
25-3	2971-2973	we	person	giv	_	_
25-4	2974-2983	determine	_	_	_	_
25-5	2984-2985	a	object[142]	new[142]	_	_
25-6	2986-2996	structural	object[142]	new[142]	_	_
25-7	2997-3002	model	object[142]	new[142]	_	_
25-8	3003-3006	for	object[142]	new[142]	_	_
25-9	3007-3010	the	object[142]|object[144]	new[142]|new[144]	_	_
25-10	3011-3022	full-length	object[142]|object[144]	new[142]|new[144]	_	_
25-11	3023-3028	human	object[142]|object[144]	new[142]|new[144]	_	_
25-12	3029-3034	DHDDS	object[142]|abstract|object[144]	new[142]|giv|new[144]	_	_
25-13	3035-3044	homodimer	object[142]|object[144]	new[142]|new[144]	_	_
25-14	3045-3050	using	_	_	_	_
25-15	3051-3053	an	abstract[145]	new[145]	_	_
25-16	3054-3065	integrative	abstract[145]	new[145]	_	_
25-17	3066-3074	approach	abstract[145]	new[145]	_	_
25-18	3075-3079	that	_	_	_	_
25-19	3080-3088	combines	_	_	_	_
25-20	3089-3097	multiple	abstract[146]	new[146]	_	_
25-21	3098-3105	sources	abstract[146]	new[146]	_	_
25-22	3106-3108	of	abstract[146]	new[146]	_	_
25-23	3109-3120	information	abstract[146]|abstract	new[146]|new	_	_
25-24	3121-3122	,	abstract[146]	new[146]	_	_
25-25	3123-3132	including	abstract[146]	new[146]	_	_
25-26	3133-3134	a	abstract[146]|abstract[150]	new[146]|new[150]	_	_
25-27	3135-3152	radioligand-based	abstract[146]|abstract[150]	new[146]|new[150]	_	_
25-28	3153-3159	enzyme	abstract[146]|object|abstract[150]	new[146]|giv|new[150]	_	_
25-29	3160-3168	kinetics	abstract[146]|abstract|abstract[150]	new[146]|new|new[150]	_	_
25-30	3169-3174	assay	abstract[146]|abstract[150]	new[146]|new[150]	_	_
25-31	3175-3176	,	abstract[146]	new[146]	_	_
25-32	3177-3191	size-exclusion	abstract[146]|object|abstract[154]	new[146]|new|new[154]	_	_
25-33	3192-3206	chromatography	abstract[146]|object|abstract[154]	new[146]|new|new[154]	_	_
25-34	3207-3218	multi-angle	abstract[146]|abstract[154]	new[146]|new[154]	_	_
25-35	3219-3224	light	abstract[146]|object|abstract[154]	new[146]|new|new[154]	_	_
25-36	3225-3235	scattering	abstract[146]|abstract[154]	new[146]|new[154]	_	_
25-37	3236-3237	(	abstract[146]	new[146]	_	_
25-38	3238-3246	SEC-MALS	abstract[146]|object	new[146]|new	_	_
25-39	3247-3248	)	abstract[146]	new[146]	_	_
25-40	3249-3250	,	abstract[146]	new[146]	_	_
25-41	3251-3262	small-angle	abstract[146]|abstract[157]	new[146]|new[157]	appos	25-45[0_157]
25-42	3263-3268	X-ray	abstract[146]|object|abstract[157]	new[146]|new|new[157]	_	_
25-43	3269-3279	scattering	abstract[146]|abstract[157]	new[146]|new[157]	_	_
25-44	3280-3281	(	abstract[146]	new[146]	_	_
25-45	3282-3286	SAXS	abstract[146]|abstract	new[146]|giv	_	_
25-46	3287-3288	)	abstract[146]	new[146]	_	_
25-47	3289-3290	,	abstract[146]	new[146]	_	_
25-48	3291-3294	and	abstract[146]	new[146]	_	_
25-49	3295-3303	hydrogen	abstract[146]|abstract	new[146]|new	appos	25-51[162_0]
25-50	3304-3305	–	_	_	_	_
25-51	3306-3315	deuterium	substance|abstract[162]	new|giv[162]	appos	25-55[0_162]
25-52	3316-3324	exchange	event|abstract[162]	new|giv[162]	_	_
25-53	3325-3342	mass-spectrometry	abstract[162]	giv[162]	_	_
25-54	3343-3344	(	_	_	_	_
25-55	3345-3351	HDX-MS	abstract	giv	_	_
25-56	3352-3353	)	_	_	_	_
25-57	3354-3355	.	_	_	_	_
